Vertex flexes its dealmaking muscle

Vertex has been seeking collaborations in the rare muscular diseases Duchenne muscular dystrophy and myotonic dystrophy type 1 for some time, making deals with Crispr Therapeutics and Exonics Therapeutics in 2019 and Affinia Therapeutics a year later.

In the past three months it has signed up two more partners, Entrada Therapeutics and Tevard Biosciences. But all Vertex’s collaborations remain at the research stage, and a look at the pipelines for these disorders show that the group is playing the long game.